Amgen To Webcast Investor Call At EADV 2021

Rhea-AI Summary

Amgen will host a webcast call on Oct. 4, 2021, at 8:30 a.m. ET, in conjunction with the EADV 2021 Congress. The call will feature David M. Reese, M.D., and other management discussing clinical data, particularly from the AMG 451/KHK4083 Phase 2 trial for moderate-to-severe atopic dermatitis. The investor call is open to the public and can be accessed via Amgen’s website. A replay will be available for 90 days post-event.

THOUSAND OAKS, Calif., Sept. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress. On Monday, Oct. 4, 2021, at 8:30 a.m. ET,  David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen's management team, will discuss clinical data being presented at EADV, including data from the AMG 451/KHK4083 Phase 2 trial in patients with moderate-to-severe atopic dermatitis, as well as our broader inflammation portfolio.

Live audio of the investor call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. 

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.   

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks
Michael Strapazon, 805-313-5553 (media)
Trish Rowland, 805-447-5631(media) 
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-eadv-2021-301388248.html

SOURCE Amgen

FAQ

What is Amgen's upcoming event on Oct. 4, 2021, related to EADV?

Amgen will host a webcast call to discuss clinical data from the EADV 2021 Congress, featuring insights on the AMG 451/KHK4083 Phase 2 trial.

Who will represent Amgen during the webcast call at EADV 2021?

David M. Reese, M.D., executive vice president of Research and Development, will lead the discussion along with other management team members.

How can I access the Amgen webcast on Oct. 4, 2021?

The webcast can be accessed on Amgen's website under the Investors section.

Will the Amgen webcast from EADV 2021 be available for replay?

Yes, the webcast will be archived and available for replay for at least 90 days after the event.

What clinical data will Amgen present during the EADV 2021 Congress?

Amgen will present data from the AMG 451/KHK4083 Phase 2 trial concerning moderate-to-severe atopic dermatitis.